Asterias Biotherapeutics, Inc. (AST)

Trade AST now with
1/24/2019 7:09:14 AM Asterias Provides Top Line 12 Month Data Update For Its OPC1 Phase 1/2a Clinical Trial In Severe Spinal Cord Injury
11/27/2018 7:17:21 AM Asterias Biotherapeutics Announces Fourth Patient Dosed In First-in-Human Clinical Study Of Immunotherapy VAC2 In NSCLC
11/8/2018 6:49:54 AM BioTime Q3 Net Income $66.7 Mln Or $0.53/shr Vs. $14.3 Mln Or $0.12/shr Last Year
11/8/2018 6:39:47 AM BioTime To Acquire All Remaining Outstanding Common Stock Of Asterias
10/1/2018 7:14:35 AM Asterias Biotherapeutics Enters Into Two New Agreements With Affiliate Of Novo Nordisk
9/20/2018 7:07:13 AM FDA Accepts Asterias Biotherapeutics’ Request To Discuss Next Phase Of Development For OPC1 Clinical Development Program
9/18/2018 7:00:36 AM BioTime Implements New Leadership Structure; Appoints Brian Culley As CEO
9/17/2018 1:01:00 AM BioTime Updates Timeline For Distribution Of AgeX Shares To BioTime Shareholders
8/16/2018 8:03:46 AM AgeX Therapeutics Acquires Certain Patents And Patent Applications From Escape Therapeutics
8/2/2018 8:08:09 AM BioTime Announces New Strategic Alignment Between AgeX Therapeutics And Juvenescence
7/12/2018 7:07:53 AM Asterias Biotherapeutics Announces New Exclusive License Deal With The Regents Of University Of California For Stroke IP
6/29/2018 7:04:19 AM BioTime Secures Grant From The National Institutes Of Health
6/12/2018 7:08:18 AM Asterias Biotherapeutics Says First Patient Dosed In First-in-Human Clinical Study Of Immunotherapy AST-VAC2 In NSCLC
6/11/2018 7:00:57 AM AgeX Therapeutics Closes On $5 Mln Strategic Investment From Juvenescence
6/5/2018 7:14:00 AM Asterias Biotherapeutics Says Independent DMC Completes Intermediate Review Of AST-OPC1 Clinical Trial
6/5/2018 7:03:57 AM AgeX Therapeutics Appoints John Mauldin To Its Board